These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 30831507)

  • 41. Hand-foot syndrome variant in a dihydropyrimidine dehydrogenase-deficient patient treated with capecitabine.
    Saif MW; Elfiky A; Diasio R
    Clin Colorectal Cancer; 2006 Sep; 6(3):219-23. PubMed ID: 17026792
    [TBL] [Abstract][Full Text] [Related]  

  • 42. 5-FU-induced neurotoxicity in cancer patients with profound DPD deficiency syndrome: a report of two cases.
    Cordier PY; Nau A; Ciccolini J; Oliver M; Mercier C; Lacarelle B; Peytel E
    Cancer Chemother Pharmacol; 2011 Sep; 68(3):823-6. PubMed ID: 21553285
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Dihydropyrimidine dehydrogenase deficiency screening for management of patients receiving a fluoropyrimidine: Results of two national practice surveys addressed to clinicians and biologists].
    Loriot MA; Masskouri F; Carni P; Le Malicot K; Seitz JF; Michel P; Legoux JL; Bouché O; André T; Faroux R; Delaloge S; Malka D; Guigay J; Thariat J; Thomas F; Barin-Le-Guellec C; Ciccolini J; Boyer JC; Étienne-Grimaldi MC
    Bull Cancer; 2019 Sep; 106(9):759-775. PubMed ID: 31253356
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines.
    Omura K
    Int J Clin Oncol; 2003 Jun; 8(3):132-8. PubMed ID: 12851836
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Toxicity Associated with Capecitabine in Patients Suffering from Dihydropyrimidine Dehydrogenase Deficiency.
    Bermejo-Pérez MJ; Galeote-Miguel AM; Rodelo-Haad LE; Alés-Díaz I; Durán-Ogalla G; Benavides-Orgaz M
    Chemotherapy; 2014; 60(5-6):353-5. PubMed ID: 26330092
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics.
    Mattison LK; Soong R; Diasio RB
    Pharmacogenomics; 2002 Jul; 3(4):485-92. PubMed ID: 12164772
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Toxic death-case after capecitabine + oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine deshydrogenase deficiency.
    Ciccolini J; Mercier C; Dahan L; Evrard A; Boyer JC; Richard K; Dales JP; Durand A; Milano G; Seitz JF; Lacarelle B
    Cancer Chemother Pharmacol; 2006 Aug; 58(2):272-5. PubMed ID: 16292536
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity - Ready for clinical practice?
    Meulendijks D; Cats A; Beijnen JH; Schellens JH
    Cancer Treat Rev; 2016 Nov; 50():23-34. PubMed ID: 27589829
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Profiling dihydropyrimidine dehydrogenase deficiency in patients with cancer undergoing 5-fluorouracil/capecitabine therapy.
    Mercier C; Ciccolini J
    Clin Colorectal Cancer; 2006 Nov; 6(4):288-96. PubMed ID: 17241513
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pancytopenia and Severe Gastrointestinal Toxicities Associated with 5-Fluorouracil in a Patient with Thymidylate Synthase (TYMS) Polymorphism.
    Wang B; Walsh SJ; Saif MW
    Cureus; 2016 Sep; 8(9):e798. PubMed ID: 27774364
    [TBL] [Abstract][Full Text] [Related]  

  • 51. DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update.
    Henricks LM; Opdam FL; Beijnen JH; Cats A; Schellens JHM
    Ann Oncol; 2017 Dec; 28(12):2915-2922. PubMed ID: 29045513
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing severe adverse reactions to 5-fluorouracil-based chemotherapy.
    Morrison GB; Bastian A; Dela Rosa T; Diasio RB; Takimoto CH
    Oncol Nurs Forum; 1997; 24(1):83-8. PubMed ID: 9007910
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dihydropyrimidine dehydrogenase deficiency as a cause of fatal 5-Fluorouracil toxicity.
    Fidai SS; Sharma AE; Johnson DN; Segal JP; Lastra RR
    Autops Case Rep; 2018; 8(4):e2018049. PubMed ID: 30775324
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity.
    Van Kuilenburg AB; Vreken P; Beex LV; Meinsma R; Van Lenthe H; De Abreu RA; van Gennip AH
    Eur J Cancer; 1997 Nov; 33(13):2258-64. PubMed ID: 9470816
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [A Case of Colon Cancer with DPD Deficiency That Showed Severe Myelosuppression by CapeOX Adjuvant Chemotherapy after Colon Resection].
    Watanabe H; Arita S; Takeuchi T; Oshima Y; Koike N
    Gan To Kagaku Ryoho; 2018 Nov; 45(11):1661-1664. PubMed ID: 30449859
    [TBL] [Abstract][Full Text] [Related]  

  • 56. 5-Fluorouracil Neurotoxicity in a Patient With Normal Dihydropyrimidine Dehydrogenase Activity.
    Natarajan U; Onyechi A; Ohemeng-Dapaah J
    Cureus; 2023 Dec; 15(12):e49898. PubMed ID: 38174188
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer.
    Humerickhouse RA; Dolan ME; Haraf DJ; Brockstein B; Stenson K; Kies M; Sulzen L; Ratain MJ; Vokes EE
    Clin Cancer Res; 1999 Feb; 5(2):291-8. PubMed ID: 10037177
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Individualizing therapy with 5-fluorouracil related to dihydropyrimidine dehydrogenase: theory and limits.
    Milano G; Etienne MC
    Ther Drug Monit; 1996 Aug; 18(4):335-40. PubMed ID: 8857547
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients.
    Di Paolo A; Danesi R; Falcone A; Cionini L; Vannozzi F; Masi G; Allegrini G; Mini E; Bocci G; Conte PF; Del Tacca M
    Ann Oncol; 2001 Sep; 12(9):1301-6. PubMed ID: 11697844
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Molecular toxicological mechanism of the lethal interactions of the new antiviral drug, sorivudine, with 5-fluorouracil prodrugs and genetic deficiency of dihydropyrimidine dehydrogenase].
    Watabe T; Ogura K; Nishiyama T
    Yakugaku Zasshi; 2002 Aug; 122(8):527-35. PubMed ID: 12187768
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.